TABLE 5.
Comparison of disc diffusion and modal MICa categorical interpretations for 140 S. pneumoniae results from two ICS laboratories using disc diffusion for six antimicrobialsa
| Antimicrobial | Number of isolates testeda,b,c | % Concordance of categorical interpretation of modal MIC | |
|---|---|---|---|
| CLSId | EUCASTe | ||
| Chloramphenicol | 145 | 93.8 (136/145) | 95.2 (138/145) |
| Clindamycin | 133 | 97.7 (130/133) | 98.5 (131/133) |
| Erythromycin | 131 | 99.2 (131/132) | 99.2 (131/132) |
| Levofloxacin | 134 | 100 (120/120) | 100 (120/120) |
| Trimethoprim/sulfamethoxazole | 146 | 88.4 (129/146) | 91.1 (133/146) |
| Vancomycin | 127 | 100 (127/127) | 100 (127/127) |
| Total | 816 | 94.7 (773/816) | 95.6 (780/816) |
a
One participating laboratory tested all six listed compounds by disc diffusion consistently for all panels; one participant performed disc diffusion for the 2009AB panels for chloramphenicol and trimethoprim/sulfamethoxazole only.
b
Number of tested isolates varied due to non-viable isolates following shipping, and vancomycin not being tested in the first distribution.
c
For this report, isolates with no modal MIC were excluded from calculations.
d
Using CLSI M100, 33rd Edition, 2023.
e
Using EUCAST Breakpoint tables for interpretation of MICs and zone diameters, Version 13.0, 2023.